6-cyclopropylamino-nicotinic acid | 960060-88-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-cyclopropylamino-nicotinic acid
• 英文别名: 6-(Cyclopropylamino)pyridine-3-carboxylic acid
• CAS: 960060-88-2
• 化学式: C₉H₁₀N₂O₂
• mdl: MFCD11132008
• 分子量: 178.191
• InChiKey: BJWSFKCKOOIPSA-UHFFFAOYSA-N

物化性质

• 沸点：
  389.2±27.0 °C(Predicted)
• 密度：
  1.437±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-cyclopropylamino-nicotinic acid 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 2.0h， 生成 (S)-7-(cyclopropyl(5-(3-fluoropiperidine-1-carbonyl)pyridin-2-yl)amino)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one
  参考文献：
  名称：

  [EN] 15-PGDH INHIBITORS
  [FR] INHIBITEURS DE 15-PGDH

  摘要：

  Described herein are 15-PGDH inhibitors and methods of utilizing 15-PGDH inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

  公开号：

  WO2023137356A1
• 作为产物：
  描述：

  6-氯烟酸 、 环丙胺 以 异丙醇 为溶剂， 反应 0.67h， 以34%的产率得到6-cyclopropylamino-nicotinic acid
  参考文献：
  名称：

  3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b

  摘要：

  A series of 3-nitro-4-substituted-aminobenzoic acids were prepared and found to act as potent and highly selective agonists of the orphan human GPCR GPR109b, a low affinity receptor for niacin. No activity was observed at the closely homologous high affinity niacin receptor, GPR109a. A second series, comprising 6-amino-substituted nicotinic acids was, also prepared and several analogues showed comparable activity to the nitroaryl series. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.058

文献信息

• NEW COMPOUNDS
  申请人：HAUEL Norbert

  公开号：US20100240669A1

  公开（公告）日：2010-09-23

  The present invention relates to the compounds of general formula I wherein n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and X are defined as described hereinafter, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the medicaments containing the pharmacologically effective compounds, the preparation thereof and the use thereof.

  本发明涉及一般式I的化合物，其中n、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11和X的定义如下所述，其对映体、非对映体、混合物及其盐，特别是其与有机或无机酸或碱形成的生理上可接受的盐，具有有价值的性质，其制备方法，含有药理学有效化合物的药物，其制备方法和用途。
• Heterocyclic antiviral compounds
  申请人：Brameld Kenneth Albert

  公开号：US20100021423A1

  公开（公告）日：2010-01-28

  Compounds having the formula I wherein R 1 , R 2 , R 3 , R 4a , R 4b , R 4c , R 5 , R 6 , R 9 and n are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

  具有以下化学式I的化合物，在该式中R1、R2、R3、R4a、R4b、R4c、R5、R6、R9和n的定义如本文所述，是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。
• Amide derivatives as somatostatin receptor 5 antagonists
  申请人：Binggeli Alfred

  公开号：US20060276508A1

  公开（公告）日：2006-12-07

  This invention is concerned with compounds of the formula wherein R 1 to R 5 , R 5′ and A are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式中的化合物，其中R1至R5、R5'和A如描述和索赔中所定义，并且其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于治疗和/或预防与调节SST受体亚型5相关的疾病的方法。
• PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1893603B1

  公开（公告）日：2009-10-14
• HETEROCYCLIC ANTIVIRAL COMPOUNDS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2307372B1

  公开（公告）日：2012-04-25